<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01272466</url>
  </required_header>
  <id_info>
    <org_study_id>2006-003619-29</org_study_id>
    <nct_id>NCT01272466</nct_id>
  </id_info>
  <brief_title>Vaccination With Peptides From Anti-apoptotic Proteins in Relapsed Multiple Myeloma</brief_title>
  <official_title>Vaccination With Peptides Derived From Anti-apoptotic Proteins From the Bcl-2 Family, Administered in Combination With Montanide ISA-51 in Relation to Treatment With Proteasome Inhibitors in Patients With Relapsed Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anti-apoptotic proteins from the Bcl-2 family are known to play a key role in oncogenesis and
      are overexpressed in myeloma cells. Studies have shown that dendritic cells exposed to
      proteasome inhibition present exogene antigens better than unexposed dendritic cells.
      Patients with relapse of multiple myeloma will be offered vaccination with peptides derived
      from antiapoptotic proteins from the Bcl-2 family in combination with an immunostimulatory
      adjuvant. The vaccination will be given in relation to treatment with the proteasome
      inhibitor bortezomib.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2010</start_date>
  <primary_completion_date type="Anticipated">February 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>15 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Relapsed Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>peptides from antiapoptotic proteins</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>peptides derived from antiapoptotic proteins</intervention_name>
    <description>8 Vaccinations on day 2 and 9 in every bortezomib treatment series</description>
    <arm_group_label>peptides from antiapoptotic proteins</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinical diagnosis of multiple myeloma

          -  tissue type of HLA-A1, HLA-A2 or HLA-A3

          -  Performance status &lt; 2

          -  Adequate bone marrow - renal and liver function

          -  written informed concent

        Exclusion Criteria:

          -  candidate for bone marrow transplantation

          -  other malignancies than multiple myeloma

          -  other significant medical disease (heart-, lung or liver disease or diabetes)

          -  allergy

          -  active autoimmune disease

          -  treatment with immunosuppressive drugs

          -  treatment with other experimental drugs

          -  uncontrolled hypercalcemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lene M Knudsen, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Haematology, Odense University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Haematology, Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lene M Knudsen, M.D.</last_name>
      <phone>+4565411850</phone>
      <email>lene.meldgaard.knudsen@ouh.regionsyddanmark.dk</email>
    </contact>
    <contact_backup>
      <last_name>Niels Abildgaard, M.D.</last_name>
      <phone>+4523221584</phone>
      <email>niels.abildgaard@ouh.regionsyddanmark.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Lene M Knudsen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2011</study_first_submitted>
  <study_first_submitted_qc>January 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2011</study_first_posted>
  <last_update_submitted>January 6, 2011</last_update_submitted>
  <last_update_submitted_qc>January 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Lene Meldgaard Knudsen M.D. Head of Department</name_title>
    <organization>Department of Haematology, Odense University Hospital</organization>
  </responsible_party>
  <keyword>multiple myeloma</keyword>
  <keyword>vaccination</keyword>
  <keyword>antiapoptotic proteins</keyword>
  <keyword>proteasome inhibition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Proteasome Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

